Cardiovascular disease (CVD) remains the most formidable health adversary for women globally. Despite being the leading cause of death—claiming one in every three women annually—the medical establishment has long operated under a framework designed primarily for the male physiology. As a result, women are frequently underdiagnosed, undertreated, and mismanaged, often because their symptoms present in ways that defy traditional, male-centric clinical markers.
This critical disparity took center stage at the 2026 MedTech Conference in Boston, where industry leaders, clinicians, and innovators gathered to dissect the systemic failures in women’s heart health. Moderated by Colby Holtshouse, CEO of May Health, a high-level panel explored how the healthcare industry must pivot to address these gaps, moving from a "one-size-fits-all" approach to one that centers on biological nuance, data equity, and active patient advocacy.
The Silent Epidemic: Main Facts and Current Challenges
The consensus among experts is clear: the medical "black box" regarding female cardiovascular health is a result of decades of research bias. Women often experience cardiovascular distress differently than men. While the "Hollywood heart attack"—characterized by crushing chest pain—is the standard reference, women are more likely to experience atypical symptoms such as fatigue, shortness of breath, nausea, or back pain.
Because these symptoms are often misattributed to stress, anxiety, or menopause, the window for life-saving intervention frequently closes before a diagnosis is ever made. The panel in Boston identified four key pillars required to reverse this trend: the role of inflammation, the necessity of patient advocacy, the integration of women into clinical trial design, and the imperative for data-driven equity.
A Chronological Shift: From Exclusion to Visibility
The history of clinical research is marked by the systematic exclusion of women, often justified by concerns over hormonal fluctuations that could "complicate" trial results. This chronological exclusion has created a legacy of medical data that does not accurately reflect the population.
- Mid-20th Century to 1990s: Clinical trials for cardiovascular treatments were almost exclusively performed on male subjects. The medical community operated on the assumption that findings in men were universally applicable.
- The Early 2000s: Public health agencies began to acknowledge the sex-based differences in cardiac presentations, yet investment in sex-specific diagnostic tools lagged significantly.
- The 2020s Era: We are currently in a period of reckoning. With the rise of FemTech and a renewed focus on health equity, the conversation has moved from "Why aren’t women being studied?" to "How do we structurally overhaul the entire pipeline to account for female physiology?"
The MedTech Conference discussion marked a pivotal point in this timeline, signaling that the industry is no longer satisfied with mere acknowledgment; the demand is now for aggressive investment and policy reform.
Supporting Data: Why the "Black Box" Must Open
The urgency of this mission is underscored by sobering statistics. According to the American Heart Association and Go Red for Women, cardiovascular disease accounts for one in three female deaths. However, the complexity of female health extends beyond the heart muscle itself.
Dr. Kathleen Jordan, Chief Medical Officer at Midi Health, emphasized the interconnectedness of systemic health. "Women have more inflammation; they have more autoimmune disease," Dr. Jordan noted. "Inflammation is linked to more cardiovascular disease, dementia, and cancers. It is a black box that needs significantly more scientific rigor."
The connection between autoimmune triggers and heart disease is a burgeoning area of study. Because women are disproportionately affected by autoimmune conditions, their baseline levels of systemic inflammation are often higher, creating a unique cardiovascular risk profile that is currently not well-integrated into standard risk calculators like the Framingham Risk Score.
Official Perspectives: The Path Forward
The panelists, representing some of the most influential entities in the medical device and digital health sectors, offered a multifaceted roadmap for the future.
1. Re-evaluating the Patient Experience
Sarah Huoh, corporate vice president of public affairs at Edwards Lifesciences, highlighted the human cost of current systemic failures. She shared the case of a survivor of childhood cancer who developed valve disease years later—a long-term effect of her initial radiation therapy. Despite the clear medical history, this patient faced a grueling, years-long struggle to secure the necessary intervention.
"She had to advocate and fight for herself in this day and age," Huoh remarked. "It brings us back to the question of why? Why did she have to endure such agony to get the treatment she needed? We must listen—really listen—to the clinicians at the bedside to understand the lived reality of these patients."
2. Ending the "Afterthought" Mentality
Alicia Chong Rodriguez, founder of Bloomer Tech, challenged the investment community directly. Bloomer Tech has been at the forefront of embedding diagnostic technology into textiles and wearables specifically designed for women.
"It should come front and center that we are building for female patients," Rodriguez argued. "Too often, we see ‘women’s health’ treated as a niche category or an afterthought in the design phase. If we want to move the needle, the female patient must be the primary design consideration, not a secondary modification."
3. Enrichment and Data Equity
Dr. Laura Mauri, senior vice president and chief scientific and medical officer at Medtronic, called for a strategy of "data enrichment." Because women have been underrepresented for so long, Dr. Mauri suggested that trials should intentionally over-sample women to compensate for the historical deficit.
"We need to enrich the data," Dr. Mauri said. "This is even more critical for women of color, who face a double burden of health disparities. From an investment standpoint, we are looking at an undertreated and underserved market. Doubling down here is not just a moral imperative; it is a massive opportunity for innovation."
Implications: The Future of Women’s Heart Health
The implications of these insights are profound for the medtech industry, policymakers, and providers alike.
For Innovators and Startups: The shift toward "female-first" design is moving from a trend to a business necessity. Companies that can develop sensors, AI algorithms, and surgical tools that account for the unique anatomical and physiological differences in women will likely capture significant market share.
For Clinical Trials: The days of "sex-blind" research are ending. Regulatory bodies are increasingly likely to demand sex-disaggregated data. Future trials must demonstrate that their devices and drugs are not only safe for men but are optimized for the female biology.
For Healthcare Systems: The challenge lies in diagnostics. Hospitals and clinics must retrain triage staff and cardiologists to recognize the non-traditional symptoms of heart disease. Integrating AI-driven diagnostic tools that can flag risks based on female-specific inflammation markers could be the difference between life and death.
For Policy and Investment: As Dr. Mauri suggested, the "underserved" nature of this market represents a strategic opportunity. Venture capital and R&D budgets are beginning to align with the reality that women represent 50% of the population. As this realization takes hold, we should expect to see a surge in funding for research into autoimmune-linked heart disease, gender-specific hormone therapy, and long-term survivorship care.
Conclusion: A New Standard of Care
The discussion in Boston serves as a rallying cry. For too long, the medical community has viewed the "average patient" as a man and treated the female patient as a variation of that norm. The evidence presented by the panelists—ranging from the physiological impact of inflammation to the sociological failures of patient advocacy—suggests that the industry is ready to abandon this outdated paradigm.
To truly address the leading cause of death for women, the industry must embrace a more nuanced, inclusive, and aggressive approach. By listening to the lived experiences of patients like those described by Sarah Huoh, and by investing in the data-rich, female-centered innovation advocated by leaders like Dr. Mauri and Alicia Chong Rodriguez, we can move toward a future where heart disease is no longer a silent, misdiagnosed killer. The era of women being an "afterthought" is ending; the era of precision, equity, and informed care must now take its place.
